Corporate Governance

Company Information

Leadership

Board of Directors

General Meetings

Company Information

Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.

Number of ordinary shares: 1,699,804,122
Countries of listing: US

Country of incorporation and main country of operation

Biodexa Pharmaceuticals PLC is incorporated in England and Wales. Its main country of operation is in the UK.

Constitutional documents

Proposed New Articles of Association (pdf)
Articles of Association (pdf)
Midatech Pharma Limited – Incorporation Documents (pdf)
Midatech Pharma PLC – Certificate of Re-registration (pdf)
Change of Name Biodexa Pharmaceuticals PLC (pdf)

Securities in issue

Details of the number of shares in issue are available here.

QCA Corporate Governance Code

Biodexa Pharmaceuticals has chosen to adopt the principles of the Quoted Companies Alliance Corporate Governance Code (the “QCA Code”). The QCA Code identifies ten principles to be followed in order for companies to deliver growth in long term shareholder value, encompassing and efficient, effective and dynamic management framework accompanied by good communication to promote confidence and trust.

The sections below set out the ways in which the Group applies the ten principles of the QCA Code in support of the Group’s medium to long-term success and identified areas where Biodexa Pharmaceuticals departs from the QCA Code recommendations, is available here.

This disclosure was last reviewed and updated on 28 March 2023.

Directors responsibilities

Details of Biodexa Pharmaceuticals Board of Directors, including biographical information is available here.

The Board of Directors is responsible to the shareholders for the proper management of the Company. It intends to meet regularly to consider the strategy and direction of the Company, to review scientific, operational and financial performance and to advise on management appointments. All key operational and investment decisions are subject to Board approval. The Company Secretary is responsible for ensuring that the Board procedures are followed and applicable rules and regulations are complied with.

Board committees

The Board has three Committees, Audit, Remuneration and Nominations.

The Audit Committee comprises Simon Turton (Chair), Sijmen de Vries and Stephen Parker, and will meet formally not less than twice every year and otherwise as required. The terms of reference of the Audit Committee can be found here.

The Remuneration Committee comprises Sijmen de Vries (Chair), Stephen Parker and Simon Turton and will meet not less than twice a year and at such other times as the chairman of the committee shall require. The terms of reference of the Remuneration Committee can be found here.

The Nominations Committee comprises the full Board and is chaired by Stephen Parker. The Nominations Committee will meet not less than once a year and at such other times as the chairman of the committee shall require. The terms of reference of the Nominations Committee can be found here.

Annual reports, interim reports and RNS

Copies of the Company’s annual reports and interim financial statements may be accessed here.

Circulars

Circulars sent to shareholders are available here.

Takeover code

The City Code on Takeovers and Mergers published by the Panel on Takeovers and Mergers applies to the Company.

Advisers

Details of the Company’s nominated adviser and other key advisers may be found here.

This information was last updated on 11 May 2023.

Leadership

Core to Biodexa Pharmaceuticals strength is its highly experienced and dedicated team.

The Biodexa Pharmaceuticals team benefits from cross-functional expertise including formulation science and pharmaceutical development. With over 10 years’ experience of working together the team has translated multiple programmes from concept to clinic across three distinct technology platforms and apply extensive knowledge and expertise to deliver rapid R&D innovation and value creation.

Stephen Stamp

Stephen Stamp

CEO / CFO

Dmitry Zamoryakhin

Dmitry Zamoryakhin

Chief Scientific Officer/Chief Medical Officer

Dan Palmer

Dan Palmer

VP Technology

Fiona Sharp

Fiona Sharp

Group Financial Controller

Steve Ellul

Steve Ellul

VP Business Development

Nicola Tuckwell

Nicola Tuckwell

VP Head of Clinical Operations

Board of Directors

 Stephen Parker

Stephen Parker

Non-executive Chairman

Stephen Stamp

Stephen Stamp

CEO / CFO

Simon Turton

Simon Turton

Senior Independent Non-executive Director

Sijmen de Vries

Sijmen de Vries

Non-executive Director

Ann Merchant

Ann Merchant

Non-executive Director

Annual General Meetings & Notices

Date

Title

Document

26/05/23

Notice of General Meeting to be held on 14 June 2023

Download

22/05/23

Notice of 2023 AGM

Download

08/03/23
FAQs and Transfer Form regarding proposed AIM cancellation

Download

08/03/23

Shareholder Circular and Notice of General Meeting to be held on 24 March 2023

Download

06/01/23
Shareholder Circular and Notice of General Meeting to be held on 23 January 2023

Download

23/05/22
Notice of 2022 AGM

Download

21/05/21
Notice of 2021 AGM

Download

08/12/20
Notice of 2020 AGM

Download

12/02/20
Shareholder Circular and Notice of General Meeting to be held on 2 March 20

Download

19/06/19
Notice of 2019 AGM

Download

05/02/19
Shareholder Circular, Open Offer & Notice of General Meeting Panel Waiver

Download

28/09/18
Shareholder Circular and Notice of General Meeting to be held on 15 October 18

Download

13/08/18
Notice of 2018 AGM

Download

28/09/17

Notice of General Meeting to be held on 16 October 2017

Download

11/04/17
Notice of Annual General Meeting 2017

Download

12/10/16
Notice of General Meeting to be held on 28 October 2016

Download

11/05/16
Notice of 2016 AGM

Download

21/05/15
Notice of 2015 AGM

Download

Stock Information
Share Data
Stock Performance
Analyst Coverage
Advisor & Investor Contacts

Reports & Presentations

Interim & Annual Reports
Presentations
Corporate Governance
Company Information
Leadership
Board of Directors
General Meetings

Media

SEC Filings
News